Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Importation bill hearing

Executive Summary

House Energy and Commerce Committee will hold a hearing Sept. 26 on "Food and Drug Import Safety Act of 2007" (H.R. 3610), introduced by Rep. John Dingell, D-Mich., Frank Pallone, D-N.J., and Bart Stupak, D-Mich. (1"The Pink Sheet" Aug. 13, 2007, p. 21). The bill authorizes $300 million for fiscal years 2008 through 2012 to pay for additional inspection personnel, labs and testing. Changes to the original draft include using fees to pay for overseas inspections and identifying the country of origin on foods, drugs and devices...

You may also be interested in...



Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees

Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich

More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths

Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel